Blueprint to Close the Women%E2%80%99s Health Gap 2025

This report uses global data when available; when not possible, the analyses used data specific to 15 countries selected for more detailed examination. While measuring the contributors to the women’s health gap is complex, this approach aims to use metrics that can track directional progress using a combination of quantitative and qualitative measures.For the first year, 15 countries were selected across four income archetypes based on World Bank (2019) data.192 The selection framework focused on diverse healthcare systems and socioeconomic conditions. Three to four countries per income archetype were included, based on the largest gap size (in terms of DALY) and opportunity for improvement. In addition to diversity across income archetypes and DALYs, countries were selected based on adequate data feasibility and Alliance priorities.1.2 Selection of countries A set of seven metrics spanning the treatment efficacy gap, care delivery gap and data gap were identified, applicable to all nine prioritized women’s health conditions and for which data were available. These are accompanied by condition-specific metrics, where more detailed examinations are taken for metrics that directly correlate to closing of the women’s health gap for these conditions.1.3 Selection of metrics Seven programme-level metrics have been selected FIGURE A1 DataMedication use coverage in volume data as compared to clinical practice guidelines (CPGs) or WHO EML (where available) Undercounting the impact of conditions in women1Assessment of how many medications in CPGs are included in global volume dataMedications included in CPGs/EMLs but not tracked in volume data indicates gap in coverage for patients, and poor understanding of appropriate careGlobal Global pharmaceutical volume data (IQVIA) WHO EMLs CPGs Care deliveryPresence and comprehensiveness of CPGs focusing on female- only conditions or female- specific aspects or a conditionDifferences in uptake of interventions due to gender bias in care delivery2Assessment of how closely national CPGs follow global guidelines as a benchmarkOutdated, incomplete or missing guidelines for preventing, diagnosing and treating female-specific conditions contribute to the care delivery gap 15 deep dive countries National clinical practice guidelines, expert insights Mortality rate (if applicable) 3 Trend in WHO-reported age–standardized mortality rate over timeChanges in mortality rate over time can indicate gaps in care delivery and efficacyGlobal WHO mortality dashboard Global Cancer Observatory database EfficacyResearch funds over the past five years relative to the burden of the conditionDifferences in treatment effectiveness between men and women4Comparison of funding amount relative to burden for conditionsGlobal World RePORT database, IHME # of innovative and ready- to-market assets in the pipeline (preclinical to Phase 3) focused on the condition5Analysis of new assets in pipeline and Phase 3 assets year on yearGlobal Pharmaprojects, expert insights # of new clinical trials for a condition and locations of trials6Assessment of clinical trial distribution by income archetypeGlobal Clinicaltrials.gov # of published trials with sex-disaggregated data7Trials with sex- disaggregated data compared to prevalence split by sex across conditionsGlobal Clinicaltrials.govIncrease in funding, research and development for a condition, especially if sex- disaggregated data is analysed, are proxies for improvement in efficacyMetric Definition Value in tracking this metric Countries Source Source: MHI Blueprint to Close the Women’s Health Gap: How to Improve Lives and Economies for All 37